Document is current
Any future updates will be listed below
-
Authors
Mohr, Katharina https://orcid.org/0009-0000-5718-0549
Hobohm, Lukas https://orcid.org/0000-0002-4312-0366
Kaier, Klaus
Farmakis, Ioannis T. https://orcid.org/0000-0002-0586-6386
Valerio, Luca https://orcid.org/0000-0003-4466-0724
Barco, Stefano https://orcid.org/0000-0002-2618-347X
Abele, Christina
Münzel, Thomas https://orcid.org/0000-0001-5503-4150
Neusius, Thomas https://orcid.org/0000-0002-5097-9064
Konstantinides, Stavros https://orcid.org/0000-0001-6359-7279
Binder, Harald
Keller, Karsten https://orcid.org/0000-0002-0820-9584
-
Funding
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 11 January 2024
Accepted: 11 March 2024
First Online: 2 April 2024
Declarations
:
: KM reports no conflicts of interest. LH reports lecture/consultant fees from MSD and Janssen, outside the submitted work. K. Kaier, IF and LV report no conflict of interest. SB reports institutional research support by Bard, Boston Scientific, Medtronic, Bayer and Sanofi; and personal fee/honoraria from Boston Scientific, Penumbra and Viatris. CA, TM and TN report no conflict of interest; TM is principal investigator of the DZHK (German Center for Cardiovascular Research). SK reports lecture and advisory fees from Bayer AG, Boston Scientific, Daiichi-Sankyo, LumiraDx, MSD, Penumbra and Pfizer—Bristol-Myers Squibb; and research grants via his institution from Bayer AG, Boston Scientific, Daiichi-Sankyo, LumiraDx and Penumbra, all unrelated to the present work. HB and K. Keller report no conflict of interest.
